The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Risk Assessment

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Risk Assessment


Psychiatry related information on Risk Assessment


High impact information on Risk Assessment


Chemical compound and disease context of Risk Assessment


Biological context of Risk Assessment


Anatomical context of Risk Assessment


Associations of Risk Assessment with chemical compounds


Gene context of Risk Assessment

  • However, analyses of risk assessment behavior revealed that BRS-3-deficient mice exhibited increased 'stretched attend posture' behavior (P < 0.01, compared to wild-type mice in both the L-D box and elevated plus maze tests) while NMB-R-deficient mice exhibited decreased behavior (P < 0.05, compared to wild-type mice in both tests) [36].
  • AIM: The initial risk assessments for BRCA1/2 mutation carriers and estimates of carrier frequencies were based on extended pedigrees with a large number of symptomatic subjects [37].
  • This paper reviews some of these newer aspects of COX-2-selective inhibitors in clinical use and discusses their possible benefits and risks [38].
  • We found no correlation between MDR protein expression and the risk assessment [39].
  • In conclusion, characterization of TOP2A gene status in childhood ALL at diagnosis provides useful complementary information for risk assessment [40].

Analytical, diagnostic and therapeutic context of Risk Assessment


  1. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group. Hosking, D., Chilvers, C.E., Christiansen, C., Ravn, P., Wasnich, R., Ross, P., McClung, M., Balske, A., Thompson, D., Daley, M., Yates, A.J. N. Engl. J. Med. (1998) [Pubmed]
  2. The case against childhood cholesterol screening. Newman, T.B., Browner, W.S., Hulley, S.B. JAMA (1990) [Pubmed]
  3. Re: weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. Norsigian, J., Napoli, M., Brenner, B.A., Cody, N., Batt, S., Pearson, C.A., Potovsky-Beachell, L., Cohen, V.S. J. Natl. Cancer Inst. (2000) [Pubmed]
  4. Identification of subsets of neuroblastomas by combined histopathologic and N-myc analysis. Shimada, H., Stram, D.O., Chatten, J., Joshi, V.V., Hachitanda, Y., Brodeur, G.M., Lukens, J.N., Matthay, K.K., Seeger, R.C. J. Natl. Cancer Inst. (1995) [Pubmed]
  5. Infantile hypertrophic pyloric stenosis after pertussis prophylaxis with erythromcyin: a case review and cohort study. Honein, M.A., Paulozzi, L.J., Himelright, I.M., Lee, B., Cragan, J.D., Patterson, L., Correa, A., Hall, S., Erickson, J.D. Lancet (1999) [Pubmed]
  6. A risk-benefit assessment of tacrine in the treatment of Alzheimer's disease. Samuels, S.C., Davis, K.L. Drug safety : an international journal of medical toxicology and drug experience. (1997) [Pubmed]
  7. A risk-benefit assessment of sildenafil in the treatment of erectile dysfunction. Vitezic, D. Drug safety : an international journal of medical toxicology and drug experience. (2001) [Pubmed]
  8. A risk-benefit assessment of buspirone in the treatment of anxiety disorders. Pecknold, J.C. Drug safety : an international journal of medical toxicology and drug experience. (1997) [Pubmed]
  9. A risk-benefit assessment of moclobemide in the treatment of depressive disorders. Norman, T.R., Burrows, G.D. Drug safety : an international journal of medical toxicology and drug experience. (1995) [Pubmed]
  10. A risk-benefit assessment of risperidone for the treatment of behavioural and psychological symptoms in dementia. Zaudig, M. Drug safety : an international journal of medical toxicology and drug experience. (2000) [Pubmed]
  11. Doxycycline for travelers' diarrhea: risks and benefits. Guerrant, R.L., Hughes, J.M. N. Engl. J. Med. (1978) [Pubmed]
  12. Reductive dechlorination of DDE to DDMU in marine sediment microcosms. Quensen, J.F., Mueller, S.A., Jain, M.K., Tiedje, J.M. Science (1998) [Pubmed]
  13. HLA-DPB1 glutamate 69: a genetic marker of beryllium disease. Richeldi, L., Sorrentino, R., Saltini, C. Science (1993) [Pubmed]
  14. p53: at the crossroads of molecular carcinogenesis and risk assessment. Harris, C.C. Science (1993) [Pubmed]
  15. Induction of cytochrome P4501A1. Whitlock, J.P. Annu. Rev. Pharmacol. Toxicol. (1999) [Pubmed]
  16. Stroke prevention in nonvalvular atrial fibrillation. Albers, G.W., Atwood, J.E., Hirsh, J., Sherman, D.G., Hughes, R.A., Connolly, S.J. Ann. Intern. Med. (1991) [Pubmed]
  17. Chenodiol (chenodeoxycholic acid) for dissolution of gallstones: the National Cooperative Gallstone Study. A controlled trial of efficacy and safety. Schoenfield, L.J., Lachin, J.M. Ann. Intern. Med. (1981) [Pubmed]
  18. Distinct response to dioxin in an arylhydrocarbon receptor (AHR)-humanized mouse. Moriguchi, T., Motohashi, H., Hosoya, T., Nakajima, O., Takahashi, S., Ohsako, S., Aoki, Y., Nishimura, N., Tohyama, C., Fujii-Kuriyama, Y., Yamamoto, M. Proc. Natl. Acad. Sci. U.S.A. (2003) [Pubmed]
  19. Patient acceptance of guanethidine as therapy for mild to moderate hypertension. A comparison with reserpine. Ferguson, R.K., Rothenberg, R.J., Nies, A.S. Circulation (1976) [Pubmed]
  20. Effect of intravenous adenosine infusion on myocardial perfusion and function. Hemodynamic/angiographic and scintigraphic study. Ogilby, J.D., Iskandrian, A.S., Untereker, W.J., Heo, J., Nguyen, T.N., Mercuro, J. Circulation (1992) [Pubmed]
  21. 5' CpG island methylation of the FHIT gene is correlated with loss of gene expression in lung and breast cancer. Zöchbauer-Müller, S., Fong, K.M., Maitra, A., Lam, S., Geradts, J., Ashfaq, R., Virmani, A.K., Milchgrub, S., Gazdar, A.F., Minna, J.D. Cancer Res. (2001) [Pubmed]
  22. Functional assay for BRCA1: mutagenesis of the COOH-terminal region reveals critical residues for transcription activation. Hayes, F., Cayanan, C., Barillà, D., Monteiro, A.N. Cancer Res. (2000) [Pubmed]
  23. Vitamin D receptor gene polymorphisms are not related to bone turnover, rate of bone loss, and bone mass in postmenopausal women: the OFELY Study. Garnero, P., Borel, O., Sornay-Rendu, E., Arlot, M.E., Delmas, P.D. J. Bone Miner. Res. (1996) [Pubmed]
  24. Benzidine mechanistic data and risk assessment: species- and organ-specific metabolic activation. Whysner, J., Verna, L., Williams, G.M. Pharmacol. Ther. (1996) [Pubmed]
  25. d-limonene mechanistic data and risk assessment: absolute species-specific cytotoxicity, enhanced cell proliferation, and tumor promotion. Whysner, J., Williams, G.M. Pharmacol. Ther. (1996) [Pubmed]
  26. Both donor and recipient NOD2/CARD15 mutations associate with transplant-related mortality and GvHD following allogeneic stem cell transplantation. Holler, E., Rogler, G., Herfarth, H., Brenmoehl, J., Wild, P.J., Hahn, J., Eissner, G., Schölmerich, J., Andreesen, R. Blood (2004) [Pubmed]
  27. Inherited p53 gene mutations in breast cancer. Sidransky, D., Tokino, T., Helzlsouer, K., Zehnbauer, B., Rausch, G., Shelton, B., Prestigiacomo, L., Vogelstein, B., Davidson, N. Cancer Res. (1992) [Pubmed]
  28. Telomerase activity in head and neck squamous cell carcinoma and adjacent tissues. Mao, L., El-Naggar, A.K., Fan, Y.H., Lee, J.S., Lippman, S.M., Kayser, S., Lotan, R., Hong, W.K. Cancer Res. (1996) [Pubmed]
  29. Potential genoprotective role for UDP-glucuronosyltransferases in chemical carcinogenesis: initiation of micronuclei by benzo(a)pyrene and benzo(e)pyrene in UDP-glucuronosyltransferase-deficient cultured rat skin fibroblasts. Vienneau, D.S., DeBoni, U., Wells, P.G. Cancer Res. (1995) [Pubmed]
  30. Risk of hospitalization for upper gastrointestinal tract bleeding associated with ketorolac, other nonsteroidal anti-inflammatory drugs, calcium antagonists, and other antihypertensive drugs. García Rodríguez, L.A., Cattaruzzi, C., Troncon, M.G., Agostinis, L. Arch. Intern. Med. (1998) [Pubmed]
  31. Editorial: Risks and benefits of estrogen use. Weiss, N.S. N. Engl. J. Med. (1975) [Pubmed]
  32. Folic acid fortification of the food supply. Potential benefits and risks for the elderly population. Tucker, K.L., Mahnken, B., Wilson, P.W., Jacques, P., Selhub, J. JAMA (1996) [Pubmed]
  33. Choice of preventive treatment for isoniazid-resistant tuberculous infection. Use of decision analysis and the Delphi technique. Koplan, J.P., Farer, L.S. JAMA (1980) [Pubmed]
  34. The Food and Drug Administration and medroxyprogesterone acetate. What are the issues? Rosenfield, A., Maine, D., Rochat, R., Shelton, J., Hatcher, R.A. JAMA (1983) [Pubmed]
  35. Re: Risk/benefit assessment of tamoxifen to prevent breast cancer-still a work in progress? Gail, M.H., Costantino, J.P., Bryant, J., Croyle, R., Freedman, L., Helzlsouer, K., Vogel, V. J. Natl. Cancer Inst. (2000) [Pubmed]
  36. Role of bombesin (BN)-like peptides/receptors in emotional behavior by comparison of three strains of BN-like peptide receptor knockout mice. Yamada, K., Santo-Yamada, Y., Wada, E., Wada, K. Mol. Psychiatry (2002) [Pubmed]
  37. High frequency of BRCA1/2 germline mutations in 42 Belgian families with a small number of symptomatic subjects. Goelen, G., Teugels, E., Bonduelle, M., Neyns, B., De Grève, J. J. Med. Genet. (1999) [Pubmed]
  38. Cyclooxygenase-2 inhibition and side-effects of non-steroidal anti-inflammatory drugs in the gastrointestinal tract. Meyer-Kirchrath, J., Schrör, K. Current medicinal chemistry. (2000) [Pubmed]
  39. Multidrug resistance proteins in gastrointestinal stromal tumors: site-dependent expression and initial response to imatinib. Théou, N., Gil, S., Devocelle, A., Julié, C., Lavergne-Slove, A., Beauchet, A., Callard, P., Farinotti, R., Le Cesne, A., Lemoine, A., Faivre-Bonhomme, L., Emile, J.F. Clin. Cancer Res. (2005) [Pubmed]
  40. Modification of topoisomerase genes copy number in newly diagnosed childhood acute lymphoblastic leukemia. Guérin, E., Entz-Werlé, N., Eyer, D., Pencreac'h, E., Schneider, A., Falkenrodt, A., Uettwiller, F., Babin, A., Voegeli, A.C., Lessard, M., Gaub, M.P., Lutz, P., Oudet, P. Leukemia (2003) [Pubmed]
  41. Relation of glycemic control to diabetic microvascular complications in diabetes mellitus. Klein, R., Klein, B.E., Moss, S.E. Ann. Intern. Med. (1996) [Pubmed]
  42. Measurement of allergenic potency using the local lymph node assay. Basketter, D.A., Gerberick, G.F., Kimber, I. Trends Pharmacol. Sci. (2001) [Pubmed]
  43. Exercise thallium tomography predicts future clinically manifest coronary heart disease in a high-risk asymptomatic population. Blumenthal, R.S., Becker, D.M., Moy, T.F., Coresh, J., Wilder, L.B., Becker, L.C. Circulation (1996) [Pubmed]
  44. Characterization of a murine Ahr null allele: involvement of the Ah receptor in hepatic growth and development. Schmidt, J.V., Su, G.H., Reddy, J.K., Simon, M.C., Bradfield, C.A. Proc. Natl. Acad. Sci. U.S.A. (1996) [Pubmed]
  45. Randomized prospective evaluation of prolonged versus abbreviated intravenous heparin therapy after coronary angioplasty. Friedman, H.Z., Cragg, D.R., Glazier, S.M., Gangadharan, V., Marsalese, D.L., Schreiber, T.L., O'Neill, W.W. J. Am. Coll. Cardiol. (1994) [Pubmed]
WikiGenes - Universities